Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
F is an orotomide a novel class of
2024-08-15

F901318 is an orotomide, a novel class of antifungals, which inhibits pyridine biosynthesis by blocking dihydroorotate dehydrogenase (URA1) activity [137]. Although this pathway is conserved in humans, human URA1 is only 20% identical to its fungal homolog and it is inhibited 2000-fold less effectiv
-
Lorlatinib is an orally active brain penetrant cyclic aminop
2024-08-15

Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
br Development of lorlatinib from crizotinib to a clinical
2024-08-15

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
ARRY334543 sale br Does TIPARP contribute to the diverse
2024-08-15

Does TIPARP contribute to the diverse species sensitivity to TCDD toxicity? In chick embryo hepatocytes TIPARP was reported to mediate the TCDD-dependent suppression of hepatic gluconeogenesis, by reducing cellular NAD+ levels and reducing PCK1 expression, suggesting that ADP-ribosylation enhance
-
In glaucoma the primary retinal defect
2024-08-15

In glaucoma, the primary retinal defect appears in the GCL, whereas the other retinal layers appear normal (Kendell et al., 1995). In the current work, chronic elevation of IOP induced RGC apoptosis, especially in the GCL, and α2 adrenergic treatment reduced RGC apoptosis. Various studies have repor
-
br Materials and methods br Discussion Few studies
2024-08-14

Materials and methods Discussion Few studies have examined peripheral PACAP levels in migraineurs, and no reports have described PACAP levels in blood samples from patients with CM. Here, we demonstrated that plasma PACAP concentrations were lower in patients with interictal migraine (in both
-
br Experiment br Results and discussion
2024-08-14

Experiment Results and discussion Conclusion Introduction Tuberculosis (TB) is a chronic specific bacterial infection caused by bacteria of the Mycobacterium tuberculosis [1]. TB remains one of the deadliest diseases in the world. It is the second leading infectious cause of death after
-
br Material and methods br Results br Discussion
2024-08-14

Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De
-
A rational approach for the design of new steroid
2024-08-14

A rational approach for the design of new steroid compounds as possible competitive inhibitors of CYP17 include chemical modification at C17 of the enzyme's natural substrates, pregnenolone (1) and progesterone (2), introducing groups with moderate to strong dipole properties at C20, such as oxime a
-
AXL is a member of the TAM Tyro Axl
2024-08-14

AXL is a member of the TAM (Tyro3, Axl, Mer) family of receptor tyrosine kinases (RTKs) [4]. Elevated AXL expression could promote oncogenic processes such as cell growth, migration, invasion, and epithelial-to-mesenchymal transition (EMT), which substantially contribute to tumor progression and poo
-
br Conflict of interest br Introduction Ovarian cancer
2024-08-14

Conflict of interest Introduction Ovarian cancer is the most lethal gynecological malignancy, and ranks as the fifth leading cause of cancer death among women. The American Cancer Society estimates that about 22,280 new ovarian cancer cases and 14,240 deaths will occur in the United States in
-
Although we have achieved a
2024-08-14

Although we have achieved a great deal of success in the development of tools to understand autophagy in health and disease, highly specific reagents for autophagy manipulation and deep knowledge of autophagy is required to advance the research in therapeutic treatment. Better disease (ischemia) ani
-
Human lipoxygenase exists in two forms
2024-08-14

Human 15-lipoxygenase exists in two forms, named 15-LOX-1 (also named 12/15-LOX, 15-LO-1) and 15-LOX-2. Several reports indicate that 15-LOX-1 has a pathophysiological role in respiratory inflammatory diseases, in particular asthma. Increased activity of 15-LOX-1 is displayed in the respiratory trac
-
Tumor suppressor ARF regulates the activity of p
2024-08-14

Tumor suppressor ARF regulates the activity of p53 by inhibiting the functions of Mdm2. ARF is induced by hyperproliferative signals emanating from oncogenic Ras, overexpressed c-myc, and from deregulated E2F . ARF prevents p53 degradation and leads to increased p53 function by sequestering Mdm2 to
-
APJ receptor expression is altered in various cardiovascular
2024-08-14

APJ receptor expression is altered in various cardiovascular diseases, and both increases as well as decreases in APJ receptor expression have been reported. A decrease in mRNA and protein levels of APJ receptors was observed in patients with ischemic heart disease or idiopathic dilated cardiomyopat
16611 records 104/1108 page Previous Next First page 上5页 101102103104105 下5页 Last page